TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06621045: PIVOT-006: Phase 3 Randomized Study of Adjuvant Cretostimogene Grenadenorepvec in Intermediate-Risk Non-Muscle Invasive Bladder Cancer

Sponsor: CG Oncology, Inc. · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 364 pts

Competing Trials Overlap

9 Active Trials

Excess Burn Exposure

$20,993,280

Rescue Site Savings

+$13,842,444

Unlock Full NCT06621045 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06621045 Rescue Dossier →